Recent Comments

Psychologists Study Zero-Gravity Effects on the Human Brain (1)
computer user 14 wrote: So your doing this experiment to see if zero-g hel… [More]
Insertion of tiny heart pump without surgery (1)
Md. Saif Uddin wrote: My father is aged 57 and has TVD (Tripple Vessel D… [More]
Saffron could stop blindness and cure eye disease (2)
Marilyn wrote: Do you know where I could find this article in Fre… [More]
Department of Health announces adult autism strategy (1)
Cindy Wigglesworth wrote: My 18 year old son has Asperger's, ADHD, and anger… [More]
Concerns raised over safety of 'electronic cigarettes' (7)
carlo wrote: I had a little sore throat too. I think it was bec… [More]
Skin specialists issue warning about tan jab (1)
Melanotan wrote: Because of the side effects that they found out in… [More]

<< Idera Pharmaceuticals to discuss TLR-targeted drug discovery and development programs | Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003 >>

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

15. September 2009 08:44

Hyperion Therapeutics today announced that the first patient has been enrolled in a clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate) in children ages 6-17 with urea cycle disorders (UCD). The study will evaluate the safety, tolerability, and ammonia control of glycerol phenylbutyrate compared to BUPHENYL^® (sodium phenylbutyrate). The 2-3 week trial will enroll ten children currently treated with sodium phenylbutyrate for their UCD and will be followed by a one year open-label safety extension. The pivotal efficacy study in adult UCD patients will be conducted in parallel beginning later this year.

www.hyperiontx.com

e3bc0ce1-5fbf-4b7f-87c5-2015f28bec79|0|.0

Posted in: Child Health News | Drug Trial News

Tags: Amenorrhea, Body Odor, Brain, Congestive Heart Failure, Edema, Gastroenterology, Haloperidol, Heart Failure, Hepatology, Hypersensitivity, Metabolism, Valproic Acid

Musculoskeletal injuries more prevalent among female athletesFemale athletes experience dramatically higher rates of specific musculoskeletal injuries and medica...Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trialHyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II...King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDAKing Pharmaceuticals(R), Inc. (NYSE: KG) today announced a true milestone as it marks the first comm...NanoBio presents preclinical data of NB-201 for treating burn wounds at the 2009 ICAACNanoBio Corporation today announced compelling preclinical data for NB-201, a nanoemulsion-based top...Early schizophrenia symptoms include unusually high CA1 subfield activityIn the first functional magnetic resonance imaging (fMRI) study of its kind, neurologists and psychi...Elekta Holdings appoints new CEOJames Hoey has been named CEO of Elekta Holdings with overall responsibility for all of Elekta’s Nor...Research shed new light on anergiaWith the help of a non-invasive method of monitoring human activity, doctors and researchers at Colu...Children with constipation a significant health issueAccording to new research conducted at Nationwide Children's Hospital, the burden of illness in chil...Discovery of important links between heart failure and complications during non-cardiac surgeryIn the largest study of its kind in the U.S., researchers from Duke University have identified a pos...How do we choose our mates?For quite some time now, scientists suspect that it is not for looks or fashion, neither for love or...Common antipsychotic drug for methamphetamine overdose may damage brain cellsA common antipsychotic drug used in emergency rooms to treat methamphetamine overdose damages nerve ...SLU Liver Center to study effectiveness of tenofovir in treating hepatitis BSaint Louis University School of Medicine researchers are studying the effectiveness of a drug for p...

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Add comment

Quirky Comment Title
Name*
E-mail* (Will show your Gravatar icon)
Country Country flag

b i u quote

Comment
Preview

Notify me when new comments are added

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Recent Articles

Free!

Recent Comments

Twitter

Information

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Medical News Cloud

Recent Articles